These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 28489722)
21. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
22. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465 [TBL] [Abstract][Full Text] [Related]
23. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396 [TBL] [Abstract][Full Text] [Related]
24. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Schaal S; Kaplan HJ; Tezel TH Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial. Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407 [TBL] [Abstract][Full Text] [Related]
28. Clinical Features of Herpes Simplex Keratitis in a Korean Tertiary Referral Center: Efficacy of Oral Antiviral and Ascorbic Acid on Recurrence. Kim GN; Yoo WS; Park MH; Chung JK; Han YS; Chung IY; Seo SW; Yoo JM; Kim SJ Korean J Ophthalmol; 2018 Oct; 32(5):353-360. PubMed ID: 30311457 [TBL] [Abstract][Full Text] [Related]
29. Serum anti-endothelial cell antibodies in patients with age-related macular degeneration treated with intravitreal bevacizumab. Kubicka-Trząska A; Wilańska J; Romanowska-Dixon B; Sanak M Acta Ophthalmol; 2016 Nov; 94(7):e617-e623. PubMed ID: 27329255 [TBL] [Abstract][Full Text] [Related]
30. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results. Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma. Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029 [TBL] [Abstract][Full Text] [Related]
32. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin(®) ) in neovascular age-related macular degeneration. Bonnin P; Pournaras JA; Lazrak Z; Cohen SY; Legargasson JF; Gaudric A; Levy BI; Massin P Acta Ophthalmol; 2010 Sep; 88(6):641-5. PubMed ID: 19563370 [TBL] [Abstract][Full Text] [Related]
33. Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. Hanhart J; Comaneshter DS; Freier Dror Y; Vinker S BMC Ophthalmol; 2017 Oct; 17(1):189. PubMed ID: 29017506 [TBL] [Abstract][Full Text] [Related]
34. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications. Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942 [TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration. Tao Y; Jonas JB J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625 [TBL] [Abstract][Full Text] [Related]
36. Initial utilization of aflibercept in exudative age-related macular degeneration. Cho H; Weber ML; Shah CP; Heier JS Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352 [TBL] [Abstract][Full Text] [Related]
37. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. Nesmith BL; Ihnen M; Schaal S Retina; 2014 Dec; 34(12):2423-30. PubMed ID: 25062438 [TBL] [Abstract][Full Text] [Related]
38. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Bakri SJ; Couch SM; McCannel CA; Edwards AO Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278 [TBL] [Abstract][Full Text] [Related]
39. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL; Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198 [TBL] [Abstract][Full Text] [Related]
40. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Shimura M; Nakazawa T; Yasuda K; Shiono T; Iida T; Sakamoto T; Nishida K Am J Ophthalmol; 2008 May; 145(5):854-61. PubMed ID: 18328456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]